Idecaptagene vicleucel (Ide-cel) was approved for treating multiple myeloma (MM) by targeting B cell maturation antigen (BCMA) and including 41BB-costimulation [11,38]. The gene discussed is TNFRSF17; the disease is plasma cell myeloma.